CRISPR in the clinic
CRISPR-Cas9 is a genetic tool that can perform
molecular surgery on the DNA of a cell. Fundamentally altering the code of life
allows scientists to insert and remove genes.
For the first time in a milestone study, CRISPR-Cas9
has been implemented in a clinical setting to alleviate blindness in an
untreatable genetic condition known as Leber’s congenital amaurosis.
A single participant with Leber’s congenital amaurosis
10 (LCA10), has been administration CRISPR-Cas9 through injection into the eye
near photo-receptor cells (which detect light and color). If successful it may
reverse the disease by removing a single mutation in the DNA - allowing sight.
This form of treatment is considered safe since
CRISPR-Cas9 stays locally in the eye, and therefore should not travel to other
sites of the body.
The estimated time-frame is a month before vision is
restored. Success of this trial may result in 18 more patients commencing with
treatment in the next trial phase.
Mark Pennesi from Oregon Health & Science
University in Portland said to Nature - 'This is one of the few diseases
where we think you could actually get an improvement in vision'.
This is a historical moment for genetic editing and
life on earth. If insertion of CRISPR-Cas9 into the body proves successful, the
gene editing tool will be considered to harness unparalleled potential. Paving
the way to address the estimated 1 in 2000 world-wide suffering from single
gene retinal inherited mutations.
Comments
Post a Comment